Advertisement

Biological Action of Insulin-Like Growth Factor-I In Vivo

  • Naomi Hizuka
  • Kazue Takano
  • Kumiko Asakawa
  • Izumi Sukegawa
  • Reiko Horikawa
  • Hiroyuki Kikuchi
  • Kazuo Shizume
Part of the Serono Symposia, USA book series (SERONOSYMP)

Abstract

It has been well known that somatomedin-C/insulin-like growth factor-I (SmC/IGF-I) stimulates cell proliferation and cell differentiation and an insulin-like action in vitro (1). However, there have been only a few reports on the effects of SmC/IGF-I in vivo because of scarcity of pure extracted SmC/IGF-I (2–4). Recently, insulin-like growth factor-I (IGF-I) has been synthesized by recombinant DNA technology (5–7). With the availability of large quantities of the biosynthetic IGF-I, the biological effects of IGF-I in vivo in rats have been studied (8–12). In this paper, the results of our study for biological action of IGF-I in vivo are reported.

Keywords

Blood Urea Nitrogen Level Serum Total Cholesterol Level Body Body Weight Length 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zapf J, Schimid CH, Froesch ER. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endocrinol Metab 1984; 13: 3–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Van Buul-Offers S, Van den Brande JL. Effect of growth hormone and peptide fractions containing somatomedin activity on growth and cartilage metabolism of snell dwarf mice. Acta Endocrinol (Copenh) 1979; 92: 242–57.Google Scholar
  3. 3.
    Schoenle E, Zapf J, Humbel RE, Froesch ER. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 1982; 296: 252–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Schoenle E, Zapf J, Hauri C, Steiner T, Froesch ER. Comparison of in vivo effects on insulin-like growth factor I and II and growth hormone in hypophysectomized rats. Acta Endocrinol (Copenh) 1985; 108: 167–74.Google Scholar
  5. 5.
    Niwa M, Sato S, Saito Y, et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin-like growth factor I) and Val-somatomedin C. Ann NY Acad Sci 1986; 469: 31–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Schalch D, Reismann D, Emler C, et al. Insulin-like growth factor I/somatomedin C (IGF-I/Sm C): comparison of natural, solid phase synthetic and recombinant DNA analog peptides in two radioligand assays. Endocrinology 1984; 115: 2490–2.PubMedCrossRefGoogle Scholar
  7. 7.
    Horlein D, Buell G, Schultz F, Hirschi M, Burleigh BD. Characteriza tion of two forms of somatomedin-C produced by recombinant bacteria [Abstract No. 250]. 67th Annual Meeting of The Endocrine Society, Baltimore, 1985.Google Scholar
  8. 8.
    Hizuka N, Takano K, Shizume K, et al. Insulin-like growth factor I stimulates growth in normal growing rats. Eur J Pharmacol 1986; 125: 143–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Zapf J, Hauri C, Waldvogel M, Froesch ER. Acute metabolic effects and half lives of intravenously administered insulinlike growth factor I and II in normal and hypophysectomized rats. J Clin Invest 1986; 77: 1768–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Scheiwiller E, Guler H-P, Merryweather J, et al. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 1986; 323: 169–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Valliant SW, Peters M, Finley S, Fagin K. Insulin-like growth factor-I[Thr59]: hypoglycemic potency and pharmacokinetics in conscious rats [Abstract No. 392], 68th Annual Meeting of The Endocrine Society, Anaheim, 1986.Google Scholar
  12. 12.
    Asada T, Seki J, Horiai H, et al. Bioactivity of IGF-I/somatomedin C produced by recombinant DNA technology [Abstract No. 351]. Folia Endocrinol Japon 1985; 61 (suppl): 1030.Google Scholar
  13. 13.
    Miyakawa M, Hizuka N, Takano K, et al. Radioimmunoassay for insulin-like growth factor I (IGF-I) using biosynthetic IGF-I. Endocrinol Jpn 1986; 33: 795–801.PubMedCrossRefGoogle Scholar
  14. 14.
    Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 1980; 51: 781–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Takano K, Hizuka N, Shizume K, Hasumi Y, Kogawa M, Tsushima T. Effect of insulin and nutrition on serum levels of somatomedin A in the rat. Endocrinology 1980; 107: 1614–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Phillips LS, Orawski AT. Nutrition and somatomedin III. Diabetic control, somatomedin, and growth in rats. Diabetes 1977; 26: 864–9.PubMedGoogle Scholar
  17. 17.
    Seki J, Asada T, Horiai H, et al. Biological activity of IGF-I/Somatomedin C produced by recombinant DNA technology; insulinlike effect [Abstract No. 798]. Folia Endocrinol Japon 1986; 62(suppl) :495.Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Naomi Hizuka
    • 1
    • 2
  • Kazue Takano
    • 1
    • 2
  • Kumiko Asakawa
    • 1
    • 2
  • Izumi Sukegawa
    • 1
    • 2
  • Reiko Horikawa
    • 1
    • 2
  • Hiroyuki Kikuchi
    • 3
  • Kazuo Shizume
    • 1
    • 2
  1. 1.Department of Medicine, Institute of Clinical EndocrinologyTokyo Women’s Medical CollegeTokyoJapan
  2. 2.Research LaboratoryThe Foundation for Growth ScienceTokyoJapan
  3. 3.Fujisawa Pharmaceutical Co.OsakaJapan

Personalised recommendations